Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: Results of a long-term follow-up

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 2, 2005, Pages 125-132

  Kasperlik Zaluska, Anna A ^a,c   Cichocki, Andrzej ^b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c BIELANSKI HOSPITAL   (Poland)

Author keywords

Adrenocortical cancer; Cushing's syndrome; Mitotane; o,p' DDA; o,p' DDD; o,p' DDE

Indexed keywords

DRUG METABOLITE; FLUDROCORTISONE; HYDROCORTISONE; MITOTANE; PREDNISOLONE;

ADRENAL CANCER; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CUSHING SYNDROME; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; MALE; METASTASIS; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOTANE;

EID: 28444446270     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Allolio B, Hahner S, Weismann D, Fassnacht M (2004) Management of adrenocortical carcinoma. Clin Endocr 60: 273-287.
2. Andersen A, Warren DJ, Nome O, Vesterhus L, Slordal L (1995) A high pressure liquid Chromatographic method for measuring mitotane [1,1-(o,p'-dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(dichlorodiphenyl) -2,2-dichloroethene in plasma. Ther Drug Monit 17: 526-531.
3. Andersen A, Kasperlik-Zaluska AA, Warren DJ (1999) Determination of mitotane (o,p'-DDD) and its metabolites o,p'-DDA and o,p'-DDE in plasma by high performance liquid chromatography. Ther Drug Monit 21: 355-359.
4. Bergenstal DM, Hertz R, Lipsett MB, Moy RH (1960) Chemotherapy of adrenocortical cancer with o,p'-DDD. Ann Intern Med 53: 672-682.
5. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L (1998) Mitotane associated with Etopozide, Doxorubicin and Cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 83: 2194-2200.
6. Carpenter PC (1993) Mitotane failure in adrenocortical cancer: where next? Cancer 71: 2900-2901.
7. Dackiw APB, Lee JE, Gagel RF, Evans DB (2001) Adrenal cortical carcinoma. World J Surg 25: 914-926.
8. Dickstein G, Shechner C, Arad E, Best L-A, Nativ O (1998) Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocr Metab 83: 3100-3103.
9. Folkman J (1995) Clinical applications of research on angiogenesis. N Eng J Med 333: 1757-1763.
10. Haak HR, Hermans J, van de Velde CJH, Lentjes EGWM, Goslings BM, Fleuren G-J, Krans HMJ (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69: 947-951
11. Hartwig W, Massalski W, Kasperlik-Zaluska A, Migdalska B, Szamatowicz J, Jakowicki J (1968) Hormonally active carcinoma of the adrenal cortex treated with o,p'-DDD. Pol Endocr J 79:57-69.
12. Hough AJ, Hollifield JW, Page DL, Hartmann WH (1979) Prognostic factors in adrenal cortical tumors: a mathematical analysis of clinical and morphologic data. Am J Clin Pathol 72: 390-399.
13. Hutter AM Jr, Kayhoe DE (1966) Adrenal cortical carcinoma. Results of treatment with o,p'-DDD in 138 patients. Am J Med 41: 581-592.
14. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM (1995) Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75: 2587-2591.
15. Kasperlik-Zaluska AA, Migdalska BM, Makowska AM (1998) Incidentally found adrenocortical carcinoma. A study of 21 patients. Eur J Cancer 34: 1721-1724.
16. Kasperlik-Zaluska AA (2000) Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med. Biol Res 33: 1191-1196.
17. Kornely E, Schlaghecke R (1994) Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD. Exp Clin Endocrinol 102: 50-53.
18. Lubitz JA, Freeman L, Okun R (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223: 1109-1112.
19. Luton J-P, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat M-H, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-1201.
20. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda ECM, Caran E, Oliveira-Filho AG, Marques R, Pianowski MAD, Lacerda L, Cristofani LM, Jenkins J, Rodriguez-Galindo C, Ribeiro RC (2004) Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22: 838-845.
21. Robinson GB, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR, Stiel JN (1987) The effect of o,p'-DDD on adrenal steroid replacement requirements. Clin Endocr 27: 437-444.
22. Schteingart DE, Motazedi A, Noonan RA, Thompson NW (1982) Treatment of adrenal carcinomas. Arch Surg 117: 1142-1146.
23. Schteingart DE (2000) Conventional and novel strategies in the treatment of adrenal cancer. Braz J Med Biol Res 33: 1197-1200.
24. Summary staging guide for Cancer Surveillance, Epidemiology and End Result Reporting Program: April 1977 (1977) Bethesda, MD; US Department of Health, Education and Welfare, Public Health Service, National Institutes of Health: 12-14.
25. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L, Angeli A (2000) Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocr Metab 85: 2234-2238.
26. van Seters AP, Moolenaar AJ (1991) Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol 124: 526-533.
27. Van Slooten H, van Seters AP, Smeenk D, Moolenaar AJ (1982) o,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemoter Pharmacol 9: 85-88.
28. Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o,p-DDD: prognostic implications of serum level monitoring. Eur J Clin Oncol 20: 47-53.
29. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA (1993) Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71: 3119-3123.
30. Wajchenberg BL, Albergaria Pereira MA, Mendonca BB, Latronico AC, Carneiro PC, Ferreira Alves VA, Zerbini MCN, Liberman B, Gomes GC, Kirschner MA (2000) Adrenocortical carcinoma. Clinical and laboratory observations. Cancer 88: 711-736.
31. Weiss LM. (1984) Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Path 8: 163-169.
32. Woolen MD, King DK (1993) Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72: 3145-3155.